Concord Biotech ₹10.70 Dividend Record Date is Tomorrow, Sept 3, 2025

Concord Biotech (NSE: CONCORDBIO) has announced a dividend of ₹10.70 per equity share of face value ₹1 each, fully paid-up, for the financial year 2024–25. This reflects the company’s commitment to delivering consistent value to its shareholders through rewarding returns.

Record Date

The company’s board has fixed Wednesday, September 3, 2025, as the Record Date to determine the eligibility of shareholders entitled to receive this dividend. Shareholders holding equity shares as of this date will be considered for the payout.

Previous Dividend

Earlier, Concord Biotech had declared a dividend of ₹8.75 per share with a record date of June 22, 2024. The latest announcement highlights the company’s steady financial performance and its intent to enhance shareholder value through higher payouts.

Q1 FY26 Financial Highlights

For the quarter ended June 30, 2025, the company reported revenue from operations of ₹20,398.76 lakh, compared to ₹42,988.38 lakh in the previous quarter (March 2025) and ₹21,580.17 lakh in the same quarter last year. Including other income of ₹1,367.76 lakh, the company’s total income stood at ₹21,766.52 lakh, down from ₹43,926.78 lakh in March 2025 and slightly lower than ₹22,610.94 lakh in June 2024.

On the profitability front, the company posted a profit after tax (PAT) of ₹4,256.55 lakh for the quarter, compared to ₹14,193.76 lakh in March 2025 and ₹5,823.86 lakh in June 2024. For the full year ended March 31, 2025, the company had reported total income of ₹1,24,453.36 lakh and a PAT of ₹37,296.44 lakh.

Also Read: Dividends & Bonus Issue This Week (Sept 1–5, 2025)!

Conclusion

With the final dividend of ₹10.70 per share and September 3, 2025, as the record date, Concord Biotech continues to demonstrate its focus on rewarding shareholders. Investors should track the record date closely to ensure eligibility for the announced dividend.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.